Background The European Organisation for Research and Treatment of Cancer (EORTC)
1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients with resected …

Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint
inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has …

PURPOSE To evaluate first-line pembrolizumab monotherapy efficacy and safety in patients
with unresectable cutaneous squamous cell carcinomas (CSCCs). PATIENTS AND …

Background: Cutibacterium acnes has been identified as one of the main triggers of acne.
However, increasing knowledge of the human skin microbiome raises questions about the …

The primary goal of cancer vaccines is to induce CD8+ T cells specific for tumor-associated
antigens (TAA) but the characterization of these cells has been difficult because of the low …

Background The European Organisation for Research and Treatment of Cancer (EORTC)
1325-MG/KEYNOTE-054 trial in patients with resected, high-risk stage III melanoma …

Background. Voriconazole long-term therapy is suspected to induce cutaneous squamous
cell carcinoma (SCC), as suggested by 18 case reports worldwide and 3 retrospective studies…

Dendritic cells (DCs) are central cells in the development of antitumor immune responses,
but the number and function of these cells can be altered in various cancers. Whether these …

Background. The objective was to assess the response rate and survival of patients with
metastatic mucosal melanoma (MM) and uveal melanoma (UM) treated with anti-CTLA-4 or anti-…

Background: Melanoma incidence is higher in patients affected by Parkinson’s disease (PD)
and vice versa, but the genetic link shared by both diseases is unknown. As PARK2 is both …